Tiotropium Bromide + Formoterol FumarateThird Party Manufacturing in India

Tiotropium Bromide + Formoterol Fumarate works by optimizing dual bronchodiatory actions across different receptor systems in the lungs. Tiotropium bromide provides prolonged muscarinic M3 receptor blockade to inhibit vagal tone, while formoterol fumarate acts as a rapid-onset, long-acting beta2-agonist that stimulates adenylyl cyclase for muscle relaxation. Unlike single-agent therapies, this combination provides twenty-four-hour continuous respiratory improvement. It is highly effective and well-tolerated for severe airflow limitations. Market demand for Tiotropium Bromide + Formoterol Fumarate third party manufacturing in India is rising due to an aging population requiring effective COPD management. The long-acting anticholinergic component is verified via CAS number 136310-93-5.

Therapeutic Uses

• COPD Maintenance: Long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease.
• Airflow Obstruction Reduction: Improves forced expiratory volume in patients experiencing progressive respiratory decline.

Why Manufacturers Choose Tiotropium Bromide + Formoterol Fumarate

Celesta Healthcare utilizes a robust network of state-of-the-art inhalation production lines. Our partner facilities are WHO-GMP certified, adhering to strict particulate control and cleanroom protocols. Collaborating with a specialized Tiotropium Bromide + Formoterol Fumarate third party manufacturer in India ensures flawless market execution.